Investments, Funding & Disinvestment

The agreement builds on Haleon’s existing use of Microsoft 365 Copilot and broadens the company’s adoption of Microsoft’s AI, cloud and data technologies.

The acquisition centres on potravitug, a Phase II monoclonal antibody developed to treat BK polyomavirus-associated nephropathy (BKPyVAN).

The acquisition gives Zimmer Biomet full ownership of the iovera° system, an FDA-cleared medical device that relieves pain without medication.

The company has announced plans to expand its antibody-drug conjugate (ADC) manufacturing capabilities in Switzerland while also broadening its long-term partnership with a leading, though undisclosed, U.S.-based biopharmaceutical company.

The initiative brings together SK bioscience, global health nonprofit PATH, consulting firm Slalom and technology partner SK AX to create an evidence-based system that helps researchers evaluate vaccine candidates before they enter costly late-stage clinical trials.

The combined business will operate as Cortigent Holdings and trade on Nasdaq under the ticker symbol CRGT once the transaction closes, expected in the third quarter of 2026, subject to shareholder and regulatory approvals.

The project aims to strengthen medical education while helping Sri Lanka train more healthcare professionals to meet growing national demand.

The agreement was announced during the BIO International Convention 2026 in San Diego, California, and is expected to strengthen corneal transplantation services while improving access to sight-restoring care across the UAE and the wider region.

Under the collaboration, Insilico Medicine will use its proprietary Pharma.AI platform to identify and optimise drug candidates that meet predefined scientific and early development criteria.

Under the new arrangement, Remgro now owns 100% of Mediclinic’s Southern African operations through Mediclinic International, while IHL has taken full ownership of the Swiss-based Hirslanden Group.